Cargando…

Novel Oral Testosterone Formulation Improves Male Well Being Without Compromising International Prostate Symptom Scores

Introduction: Male hypogonadism results from insufficient secretion of testosterone (T) and is characterized by low serum T concentrations. Common symptoms of hypogonadism include decreased libido, impotence, weakness, low energy, depression and/or loss of motivation, memory and concentrating issues...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dhingra, Om P, Bernstein, James, Barnes, Shaina D, VanLaanen, Hannah, Wadlington, Natasha, Chang, Jessica
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Reproductive Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8090290/ http://dx.doi.org/10.1210/jendso/bvab048.1546

Ejemplares similares

SAT-044 Treatment of Hypogonadal Men with a New Oral Testosterone Undecanoate (TU) Formulation Improves Psychosexual, Well-Being and Body Composition and Bone Density Parameters
por: Swerdloff, Ronald S, et al.
Publicado: (2020)

SUN-046 Prevalence of Polycythaemia with Different Formulations of Testosterone Therapy in Transmasculine Individuals
por: Nolan, Brendan J, et al.
Publicado: (2020)

SAT-037 Effect of Weight on Serum Testosterone with Subcutaneous Testosterone Enanthate in Men with Testosterone Deficiency
por: Bhattacharya, Rajib, et al.
Publicado: (2020)

SUN-229 The Role of Testosterone in Spermatogenesis: Lessons from Proteome Profiling of Human Spermatozoa in Testosterone Deficiency
por: Grande, Giuseppe, et al.
Publicado: (2019)

THU645 Comparison Of LC-MS/MS Testosterone Assays Towards Standardization Of Lower Testosterone Ranges
por: Cree, Melanie G, et al.
Publicado: (2023)

Recovery of Male Reproductive Endocrine Function Following Prolonged Injectable Testosterone Undecanoate Treatment
por: Shankara-Narayana, Nandini, et al.
Publicado: (2021)

SAT-045 Free Testosterone and Cardiometabolic Parameters in Adult Men - Comparison of Algorithms for Calculation of Serum Free Testosterone
por: Holmboe, Stine Agergaard, et al.
Publicado: (2020)

OR25-4 Active Testosterone Treatment Impairs In Vitro Fertilization (IVF) Outcomes in a Female Mouse Model for Gender-Affirming Testosterone with Improvement in Outcomes Following Cessation of Testosterone Treatment
por: Moravek, Molly B, et al.
Publicado: (2022)

SAT-047 Adoption of an Age Adjusted Testosterone Reference Range Reduces Referrals to Endocrine Clinic and New Prescriptions of Testosterone
por: Dewdney, Charlotte, et al.
Publicado: (2020)

SAT-LB8 The Testosterone-To-Estradiol Ratio, Rather Than Testosterone or Estradiol Alone, Is a More Precise Marker of Metabolic-Related Outcomes in Males: Insights From a Systematic Review
por: Cadegiani, Flavio, et al.
Publicado: (2020)

SUN-044 Gonadotropin Releasing Hormone (GnRH) Agonist Therapy Induces a Sustained Reduction in Plasma Testosterone Levels and Is Well Tolerated in Transwomen Veterans
por: Gondin, Lyan, et al.
Publicado: (2020)

SAT-052 A Novel Oral Testosterone Therapy (TLANDO) Safely Restores Testosterone to Eugonadal Levels with Fixed Dose Treatment
por: DelConte, Anthony, et al.
Publicado: (2020)

Impact of Short-Acting vs Long-Acting Testosterone Therapy on Intratesticular Testosterone Using Data From Two Open-Label Randomized Clinical Trials of Testosterone Pellets, Injections, and Intranasal Gel in Hypogonadal Men
por: Kresch, Eliyahu, et al.
Publicado: (2021)

Lack of Association Between ACE2 Expression and Serum Testosterone Concentrations in Peripheral Mononuclear Cells in Males
por: Ling, Guyou, et al.
Publicado: (2021)

SUN-210 Testosterone Replacement Therapy Implicated in Osteonecrosis
por: Yang, Almira, et al.
Publicado: (2019)

SUN-217 Alternate Pathways of Testosterone Action in Testis
por: Talapatra, Arpita
Publicado: (2019)

FRI428 VTE And Testosterone Therapy: What Is The Risk?
por: Cheatham, Callie, et al.
Publicado: (2023)

FRI431 Erythrocytosis Associated With Oral Testosterone Replacement
por: Engel, Ashley A, et al.
Publicado: (2023)

MON-LB002 Compounded Testosterone Preparations Raise Testosterone Levels to Premenopausal Ranges in Postmenopausal Women With Hypo-Sexual Desire Disorder (HSDD)
por: Olson, Beatriz Rodriguez
Publicado: (2020)

SUN-206 Acute Cardiovascular Complications FromTestosterone Therapy
por: Shakir, Mohamed, et al.
Publicado: (2019)

PMON260 Cost-Effectiveness of Testosterone Treatment for Men with Hypogonadism
por: Jayasena, Channa, et al.
Publicado: (2022)

MON-206 Analysis of Concomitant AMH and Testosterone Results in 3213 Female Samples: Contrary to Common Belief, AMH and Testosterone Levels Are Not Elevated in Tandem in Most Women
por: Chandler, Donald, et al.
Publicado: (2019)

SUN-227 Monitoring Testosterone (T) Levels in Men Receiving Oral Testosterone Undecanoate (TU): Challenges Due to Post-Collection Conversion of TU-to-T and a Path Forward
por: Swerdloff, Ronald, et al.
Publicado: (2019)

SAT-LB6 First Human Trial of an Oral Native Testosterone Shows Physiological Levels of Testosterone and Dht in Both Fasted and Fed State in Hypogonadal Men
por: Newell-Price, John D C, et al.
Publicado: (2020)

Use of a Lab-Ordering Pathway to Improve Adherence to Endocrine Society (ES) Guidelines for Early AM Timing and Testosterone Assay Method for Establishing Testosterone Deficiency
por: Gammoh, Emily, et al.
Publicado: (2021)

OR25-05 Clinical Predictors Of Symptomatic Benefit In Men With Low Testosterone During Testosterone Treatment Compared With Placebo: Results Of Individual Patient And Aggregate Data Meta-analyses
por: Hudson, Jemma, et al.
Publicado: (2023)

SUN-233 Testosterone Ordering Processes in a Military Health System
por: Beauvais, Alexis, et al.
Publicado: (2019)

FRI403 The Unintended Consequences Of Applying Topical Testosterone Directly To The Scrotum
por: Melendez-Rivera, Juan Gabriel, et al.
Publicado: (2023)

PMON267 Comparison Between Single Time Point Testing and 24-Hour Average Concentration of Total Testosterone in Hypogonadal Men Treated with an Oral Testosterone Undecanoate Softgel (JATENZO®)
por: Swerdloff, Ronald, et al.
Publicado: (2022)

ODP644 Oral Dosing of Progestogenic Androgens for Male Contraception Show Low Serum Testosterone and High Acceptability in Placebo-Controlled Trials
por: Jacobsohn, Tamar, et al.
Publicado: (2022)

SUN-220 The Effect of Testosterone Nasal Gel on Reproductive Hormones and Semen Parameters
por: Masterson, Thomas, et al.
Publicado: (2019)

ODP412 High Frequency of Erythrocytosis in Hypogonadal Men on Testosterone Replacement Therapy
por: Pérez-Luis, Jesús, et al.
Publicado: (2022)

SAT367 A Rare Case of Ovarian Cellular Fibroma Producing Testosterone
por: Rai, Harpreet Kaur, et al.
Publicado: (2023)

OR25-06 The Effect of Testosterone Replacement Therapy on NAFLD in Elderly Hypogonadal Men
por: Seung Lee, Hae, et al.
Publicado: (2023)

SUN-049 Male Pattern Baldness and Waist-Hip Ratio as Markers of Arterial Stiffness in Transgender Men Undergoing Long-Term Testosterone Therapy
por: Alvares, Leonardo Azevedo Mobilia, et al.
Publicado: (2020)

FRI436 Design Of An International Male Contraceptive Efficacy Trial Using A Self-administered Daily Topical Gel Containing Testosterone And Nestorone™
por: Page, Stephanie T, et al.
Publicado: (2023)

SUN-234 Effect of Testosterone Undecanoate on Metabolic Syndrome Parameters in a Cohort of Hypogonadism
por: Yadav, Subhash Chandra, et al.
Publicado: (2019)

SAT-LB2 Elevated Testosterone Secondary to Leydig Cell Hyperplasia in Bilateral Ovaries
por: Ali, Sarah, et al.
Publicado: (2020)

OR25-6 In Men on Testosterone Therapy, Baseline Testosterone Level of <264 ng/dL is Associated with Greater Improvement in Body Composition, While Level of ≥264 ng/dL Favors Improvement in Metabolic Profile
por: Aguirre, Lina, et al.
Publicado: (2022)

PMON228 The Hidden Source of Testosterone Hypersecretion in a Female - a Thirty-Year Journey
por: Yang, Almira, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_220sivkpcjt9d4dmjpprndgfg8